Autosomal Recessive Ichthyosis
Conditions
Brief summary
KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).
Interventions
BIOLOGICALKB105
Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
OTHERPlacebo
Visually matched excipient gel
Sponsors
Krystal Biotech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
An intra-participant parallel study. Matched target areas will be randomized within the participant, such that one target area receives KB105 and the other target area will receive placebo. An additional target area may be selected to receive open-label treatment with KB105.
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Subject, or legally authorized representative, must be willing and able to give informed consent/assent 2. Aged ≥6 months 3. A genetically confirmed diagnosis of TGM1-deficient ARCI 4. Clinical diagnosis of lamellar ichthyosis 5. Two target areas located on similar anatomical regions with the same scaling severity by IGA and scaling severity ≥3 6. Subjects taking systemic retinoids must be on a stable regimen for at least 4 weeks and agree to continue to take the medication consistently throughout the study. If the subject prefers to withhold systemic retinoids during the study, then a minimum 4-week washout period is required 7. Clinically stable and in good general health Key
Exclusion criteria
1. Subject has a physical condition or other dermatological disorder (e.g., atopic, seborrheic, or contact dermatitis, psoriasis, tinea infections, etc.) which, in the Investigator's opinion, might impair evaluation of the target areas or which exposes the subject to unacceptable risk by study participation 2. Participation in another clinical study or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer 3. Any condition or illness (including a history or current evidence of substance abuse or dependence) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB105 4. Women who are pregnant or nursing 5. Subject who is unwilling to comply with contraception requirements per protocol 6. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite Investigator's Global Assessment (IGA) Responder (Comparison of proportion of responder KB105 target areas to responder placebo target areas) | Week 9 | Responder target areas are defined as: Target areas with ≥2 point reduction from baseline on IGA scaling severity at Week 9 or Target areas with ≥1 point reduction from baseline on IGA scaling severity for 2 consecutive weeks (Week 8 and Week 9) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Index of Ichthyosis Severity score change from baseline | Up to 11 weeks | Change from baseline in regional Visual Index of Ichthyosis Severity (VIIS) scaling scores, where 0 is normal and 4 is severe |
| Investigator's Global Assessment change from baseline | Up to 11 weeks | Change from baseline in Investigator's Global Assessment (IGA) scaling severity scores, where 0 is clear and 4 is severe |
| Composite regional Visual Index of Ichthyosis Severity (VIIS) responder (Comparison of proportion of responder KB105 target areas to responder placebo target areas) | Week 9 | Responder target areas are defined as: Target areas with ≥2 point reduction from baseline on VIIS scaling score at Week 9 or Target areas with ≥1 point reduction from baseline on VIIS scaling score for 2 consecutive weeks (Week 8 and Week 9) |
| Investigator's Global Assessment (IGA) 1 point responder | Week 9 | Comparison of proportion of KB105 and placebo target areas with ≥1 point reduction from baseline on IGA scaling severity for 2 consecutive weeks (Week 8 and Week 9) |
| Visual Index of Ichthyosis Severity (VIIS) 2 point responder | Week 9 | Comparison of proportion of KB105 and placebo target areas with ≥2 point reduction from baseline on regional VIIS scaling severity at Week 9 |
| Investigator's Global Assessment (IGA) 2 point responder | Week 9 | Comparison of proportion of KB105 and placebo target areas with ≥2 point reduction from baseline on IGA scaling severity at Week 9 |
Countries
United States
Contacts
Primary ContactBrittani Agostini, RN, CCRC
Outcome results
None listed